Pulmonary delivery of progestogen
View Patent ↗The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and/or fluticasone with 17-OPHC.
1. A method of preparing a composition comprising
17alpha-hydroxyprogesterone caproate, said method comprising:
(a) preparing a bulk material of a pharmaceutical formulation powder comprising 17-alphahydroxyprogesterone caproate, wherein the bulk material is prepared for milling in water using a number of cycles;
(b) milling the bulk material using at least 25 cycles and no more than 55 cycles in water to reduce the bulk material to a fine particulate, wherein the fine particulate has a Dv50 particle size that is 278 μm after cycle 25 and 2.521 μm after cycle 40 and a span distribution value of 1.636 after 25 cycles and 1.505 after 40 cycles; wherein the milling is performed in the absence of a surfactant;
(c) recovering the fine particulate by spray-drying; and
(d) blending the fine particulate with lactose monohydrate to generate the composition, wherein the lactose monohydrate comprises 90% or 99% by weight in the composition.
2. The method of claim 1 , wherein said pharmaceutical formulation powder comprises a glucocorticoid.
3. A method of preparing a composition comprising 17alpha-hydroxyprogesterone caproate, said method comprising the following steps:
a) preparing a bulk material of a pharmaceutical formulation powder comprising 17-alphahydroxyprogesterone caproate;
b) milling the bulk material in water using a number of cycles to reduce the bulk material to a fine particulate, wherein the fine particulate has a Dv50 particle size that is 2.78 μm after cycle 25 and 2.521 μm after cycle 40, and wherein the fine particulate has a span distribution value of 1.636 after 25 cycles and 1.505 after 40 cycles, wherein the number of cycles after cycle 55 results in agglomeration of the fine particulates; and
c) spray drying the fine particulate;
wherein the milling is performed in the absence of a surfactant.
4. The method of claim 3 , wherein said bulk material further comprises an excipient suitable for inhalation.
5. The method of claim 3 , wherein said pharmaceutical formulation powder further comprises a glucocorticoid.
6. The method of claim 5 , wherein said glucocorticoid is budesonide or fluticasone.
7. The method of claim 4 , wherein the excipient suitable for inhalation comprises 90% by weight of lactose monohydrate.
8. The method of claim 4 , wherein the excipient suitable for inhalation comprises 99% by weight of lactose monohydrate.